Last reviewed · How we verify
NCT03044145: CFI-EA
The Cultural Formulation Interview-Engagement Aid
NA trial testing The Cultural Formulation Interview-Engagement Aid in Communication in 45 participants. Completed in 5 September 2018.
5 September 2018
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 45 |
| Start date | 20 September 2016 |
| Primary completion | 5 September 2018 |
| Estimated completion | 5 September 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- The Cultural Formulation Interview-Engagement Aid
- The Cultural Formulation Interview-Engagement Aid (Revised)
- Treatment as usual
Conditions studied
- Communication — all drugs for Communication →
- Adherence, Patient — all drugs for Adherence, Patient →
Sponsor
New York State Psychiatric Institute
Who can join
Adults 18 to 80, any sex, with Communication or Adherence, Patient. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study consists of two projects: Project 1: The study team will create and refine the CFI-EA by enrolling 3 clinicians and 9-12 patients to test the CFI-EA's feasibility and acceptability from patient and clinician feedback in a pre-pilot trial. The study team will first train clinicians in the CFI-EA by reading over the CFI-EA treatment manual and practicing how they can use it in behavioral simulations, and then check whether participants think they can do it (feasibility) and like it (acceptability) through standard measures. Following this the study team will revise the CFI-EA based on their feedback for the comparative open trial in Phase 2. Project 2: The study team will test the revised CFI-EA against treatment as usual in a pilot trial. 3 clinicians and 12-15 patients will be enrolled in each arm. As before, the study team will first train clinicians in the revised CFI-EA by reading over the CFI-EA treatment manual and practicing how they can use it in behavioral simulations. Then, the study team will check whether participants think they can do it (feasibility) and like it (acceptability) through standard measures, and in addition will also explore any initial effects on communication behaviors among patients and clinicians and treatment engagement based on treatment retention. The specific aims are: For Project 1: 1. To pretest the CFI-EA intervention in a mental health setting through a pre-pilot open trial that explores communication mechanisms of action in terms of communication behavior and cultural content, and 2. To revise the CFI-EA intervention based on patient and clinician feedback on its feasibility and acceptability. As real-world community stakeholders for whom the CFI-EA is being developed, patients and clinicians can provide helpful perspectives on how the CFI-EA can help clinicians tailor treatment plans around patient cultural views and treatment preferences to keep patients in care. The CFI-EA will be revised around areas of maximal agreement among patients and clinicians with the help of health disparities and communication experts. For Project 2: 1. To test the revised CFI-EA's feasibility and acceptability among patients and clinicians in a pilot open trial against treatment as usual, and 2. To explore the relationship between the revised CFI-EA's effects on patient-clinician communication and treatment engagement. The study team hypothesize that clinicians using the revised CFI-EA will show more positive communication behaviors compared to clinicians delivering treatment as usual and that CFI-EA patients will stay in treatment longer. Communication behaviors will be assessed through communication analysis techniques such as the Roter Interaction Analysis System.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of consumers and health providers working in partnership on health services planning, delivery and evaluation.
Lowe D, Ryan R, Schonfeld L, Merner B, et al · · 2021 · cited 30× · PMID 34523117 · DOI 10.1002/14651858.cd013373.pub2 -
Implementing the Cultural Formulation Interview in a Community Clinic to Improve Appointment Retention: A Pilot Study.
Aggarwal NK, Chen D, Lam P, Lewis-Fernández R. · · 2022 · cited 7× · PMID 34157856 · DOI 10.1176/appi.ps.202000925
Verify or expand the search:
- PubMed search for NCT03044145
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Communication
Currently open trials in the same condition.
- NCT07303517 — AI-Driven Consent Simplification Study · recruiting
- NCT07215507 — Timing of Physician Rounds for Antepartum Patients · NA · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting
- NCT07137377 — Assessing the Impact of Therapeutic Communication on Patients' Anxiety During Elective Cesarean Sections · NA · recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03044145 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 25 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03044145.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing